Indications
Etrasimod is a sphingosine 1-phosphate receptor modulator. Doctors prescribe it to treat adults whose ulcerative colitis is moderately to severely active.
⚠️ Always consult a registered physician before taking any medicine.
Pharmacology
Etrasimod is a sphingosine 1-phosphate (S1P) receptor modulator. It binds with high affinity to S1P receptors 1, 4 and 5 (S1P1,4,5). Its activity on S1P3 is minimal (25-fold lower than Cmax at the recommended dose), and it has no activity on S1P2.
Etrasimod partially and reversibly blocks the ability of lymphocytes to leave the lymphoid organs. This lowers the number of lymphocytes in peripheral blood. How etrasimod produces its therapeutic effects in UC is not known, but it may involve less lymphocyte movement into the intestines.
Pregnancy & Breastfeeding
There is a pregnancy exposure registry that follows the outcomes of pregnancies in women who were exposed to Etrasimod while pregnant. No data are available on whether etrasimod passes into human milk, what effect it might have on a breastfed infant, or whether it changes milk production. In animal studies, female rats were given etrasimod by mouth during pregnancy and while nursing, and etrasimod was found in the plasma of their offspring. This suggests that etrasimod is excreted in milk.
⚠️ Talk to your doctor before taking any medicine during pregnancy or while breastfeeding.
Dosage Reference
⚠️ Reference ranges from official sources only. Consult your doctor for personalized dosing.